Organisation paid for research Program year 2025 Source: CMS Open Payments

Bogan Sleep Consultants LLC

Neither a doctor nor a teaching hospital

Research payments

$735,661

163 payments

Through program year 2025, Bogan Sleep Consultants LLC is reported as receiving $735,661 in research payments, across 163 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $165,878 3
2024 Research $72,415 4
2023 Research $237,213 10
2022 Research $46,222 37
2021 Research $1,500 1
2020 Research $186,439 67
2019 Research $25,995 41

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $431,369 78 payments
  2. Avadel CNS Pharmaceuticals, LLC $215,269 2 payments
  3. Jazz Pharmaceuticals Inc. $54,258 74 payments
  4. Roche Products Limited $17,086 4 payments
  5. Zevra Therapeutics Inc $8,312 1 payment
  6. Chiesi USA, Inc. $5,000 1 payment
  7. Vanda Pharmaceuticals Inc. $4,368 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Ft218 in the Treatment of Idiopathic Hypersomnia (Ih) $215,269 2 payments
  2. A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) $202,119 7 payments
  3. A Phase 1B Randomized, Double-Blind, Placebo-Controlled, Crossover Study of A Single Intravenous Infusion Dose of Tak-925 in Patients With Idiopathic Hypersomnia $89,952 45 payments
  4. A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using A Portable Electroencephalogram Device $75,086 12 payments
  5. A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions $33,385 2 payments
  6. A Phase 4 Multicenter Open-Label Single-Arm Study of Safety Tolerability Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $27,152 6 payments
  7. A Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension $25,544 40 payments
  8. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $17,086 4 payments
  9. A Phase 1B Randomized, Double-Blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of Tak-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of Cpap $12,597 6 payments
  10. A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) $9,425 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record